The CMC section of the IND contains information that has a direct influence on clinical trial supplies and failure to prepare IP that follows the requirements listed in that section can cause significant impact to a clinical trial.  This session will discuss the CMC information contained in a clinical trial regulatory filing and how it should be monitored to avoid issues wth clinical supplies.